What This Article Covers
This article summarizes published research on P21 for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.
- No human interventional trials of P21 are included in the supplied evidence set, and no cited study directly evaluates P21 in humans. The evidence set’s own uncertainties emphasize “little or no direct human evidence.”
- Although the evidence set’s claims field suggests that “direct human evidence exists,” the provided citations do not substantiate human efficacy for P21. We resolve this internal inconsistency conservatively: human efficacy and safety for P21 remain unestablished in this evidence set.
- Several citations are not P21-specific. They illuminate broader themes (e.g., proteogenomic target discovery, KRAS-directed platforms, chemical-biology tools) that are contextual to peptide research rather than direct evidence about P21.
- The pan-cancer proteogenomic work (pubmed:38917788) is a target-identification/characterization resource using human tumor data. It does not report clinical outcomes and should not be treated as a review.
Bottom Line
Based on the supplied literature, there are no human interventional studies of P21, and no paper in the evidence set directly tests P21 in humans. The evidence base presented is predominantly preclinical and contextual (proteogenomic target discovery, KRAS-focused engineering and mechanistic studies, senescence and fibrosis models, chemical-biology tools). Any human relevance in this evidence set pertains to target landscapes or engineered platforms in oncology—not to clinical efficacy or safety of P21.
Human evidence and contextual resources (not P21 efficacy)
- Pan-cancer proteogenomics expands the therapeutic target landscape (pubmed:38917788). This is a human tumor characterization resource without clinical outcome data and without P21-specific clinical testing.
- KRAS-focused development efforts (e.g., mutant KRAS peptide–targeted CAR-T engineering and orally bioavailable intracellular peptide programs: pubmed:40480232; pubmed:37463267) are translational/engineering in nature, not human trials of P21.
Preclinical and mechanistic evidence
– Structure–activity relationships for middle-size cyclic peptides that inhibit KRAS, derived from mRNA display (pubmed:38981216). – A covalent KRAS(G12C) inhibitor that induces MHC class I presentation of haptenated peptide neoepitopes, with implications for immunotherapy targeting (pubmed:36099883). – A KRAS G12V neoantigen–specific T cell receptor engineered for adoptive T-cell therapy (pubmed:37828002).
– A Klotho-derived peptide inhibits cellular senescence in a fibrotic kidney model by restoring Klotho expression via posttranscriptional regulation (preclinical/mechanistic; pubmed:38164143).
– A recombinant walnut-derived peptide ameliorates d-galactose–induced cognitive deficits in a preclinical model (pubmed:40864666).
- KRAS-directed platforms and mechanisms:
- Fibrosis and cellular senescence:
- Cognition model:
Tools, target validation, and infrastructure (not clinical efficacy)
- A turn-on fluorescent PCNA sensor (chemical-biology tool; modality not specified as peptide in the citation metadata; pubmed:33839250).
- A PAK4-targeting PROTAC developed for renal carcinoma therapy that both inhibits cancer cell proliferation and enhances immune cell responses (small-molecule chimera concept; target-validation/drug-design context; pubmed:38810561).
Evidence-tier mapping (by citation)
- pubmed:38917788 — Human tumor proteogenomic target-identification/characterization; no clinical outcomes; not P21-specific.
- pubmed:40480232 — Mutant KRAS peptide–targeted CAR-T engineering; preclinical/engineering; not P21.
- pubmed:37463267 — Development of orally bioavailable peptides to an intracellular KRAS inhibitor; medicinal chemistry/translation pathway; not P21; not clinical efficacy.
- pubmed:37828002 — Engineered TCR against KRAS G12V neoantigen; preclinical/engineering; not P21.
- pubmed:38164143 — Klotho-derived peptide reduces senescence in fibrotic kidney model; preclinical/mechanistic; not P21.
- pubmed:36099883 — KRAS(G12C) covalent inhibitor induces haptenated neoepitopes; mechanistic tumor immunology; preclinical; not P21.
- pubmed:40864666 — Recombinant walnut-derived peptide in d-galactose–induced cognitive deficit model; preclinical; not P21.
- pubmed:33839250 — Turn-on fluorescent PCNA sensor; chemical-biology tool; modality not specified as peptide; not P21.
- pubmed:38981216 — SAR of middle-size cyclic peptides as KRAS inhibitors from mRNA display; preclinical; not P21.
- pubmed:38810561 — PAK4-targeting PROTAC; small-molecule chimera; target-validation/drug-design; preclinical; not P21.
Limitations and scope boundaries
- No direct human efficacy or safety data for P21 are provided.
- Dosing, generalized safety, and off-label extrapolation are not supported by the evidence set.
- Broad anti-aging or wellness claims are unsupported.
- Mechanistic or platform-level findings (e.g., senescence modulation, neoantigen presentation, proteogenomic target expansion) should not be generalized to P21 clinical utility.
What Was Tested in Humans?
No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.
What Did Animal and Mechanistic Studies Show?
The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.
How the Evidence Fits Together
The practical reading for P21 is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.
What Is Not Established
- Broad human efficacy for P21 is not established by this article.
- Animal, cellular, or review-level findings should not be converted into human-use claims.
- Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.
Research-Use Boundary
This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.
Selected Sources
- pubmed:38917788 — Pan-cancer proteogenomics expands the landscape of therapeutic targets. https://pubmed.ncbi.nlm.nih.gov/38917788/
- pubmed:40480232 — Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. https://pubmed.ncbi.nlm.nih.gov/40480232/
- pubmed:37463267 — Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor. https://pubmed.ncbi.nlm.nih.gov/37463267/
- pubmed:37828002 — KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. https://pubmed.ncbi.nlm.nih.gov/37828002/
- pubmed:38164143 — Klotho-derived peptide 1 inhibits cellular senescence in the fibrotic kidney by restoring Klotho expression via posttranscriptional regulation. https://pubmed.ncbi.nlm.nih.gov/38164143/
- pubmed:36099883 — A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. https://pubmed.ncbi.nlm.nih.gov/36099883/
- pubmed:40864666 — Recombinant Walnut-Derived Peptide Ameliorates d-Galactose-Induced Cognitive Deficits. https://pubmed.ncbi.nlm.nih.gov/40864666/
- pubmed:33839250 — A turn-on fluorescent PCNA sensor. https://pubmed.ncbi.nlm.nih.gov/33839250/
- pubmed:38981216 — Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display. https://pubmed.ncbi.nlm.nih.gov/38981216/
- pubmed:38810561 — Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. https://pubmed.ncbi.nlm.nih.gov/38810561/
Related KRL Resources
Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.
1st Time Customers Receive 10% off their 1st order over $100.00 with CODE KRL10
Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.